Jarl Ulf Jungnelius M.D. is a licensed medical practitioner and a board-certified oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations. He worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that Dr Jungnelius held leadership positions at Takeda, Pfizer and Eli Lilly & Company, where he was responsible for clinical development of oncology programs as well as involved in business development.
Dr Jungnelius played significant roles in the clinical development of several successful oncology drugs, including gemcitabine (Gemzar®), premetrexed (Alimta®), sunitinib (Sutent®), lenalidomide (Revlimid®) and the albumin-bound nanoparticle paclitaxel (Abraxane®). He is currently engaged as Senior Oncology Advisor for TME Pharma and sits on the Board of Oncopeptides AB, Biovica International AB, Ryvu Therapeutics, and HealthCom GmbH. Dr Jungnelius received both a Bachelor of Science degree and his M.D. from the Karolinska Institute in Stockholm Sweden.
Sign up for the Beactica newsletter to receive our latest news and updates